Literature DB >> 12737444

Oral budesonide significantly improves water absorption in patients with ileostomy for Crohn disease.

K W Ecker1, A Stallmach, G Seitz, M Gierend, R Greinwald, U Achenbach.   

Abstract

BACKGROUND: In addition to their anti-inflammatory effects, steroids influence electrolyte and water transport systems in the intestinal mucosa. This study analysed the effect of the topically acting glucocorticoid budesonide on ileostomy output in patients with Crohn disease.
METHODS: Oral budesonide (3 mg/three times daily for 8 days; n = 20) was compared to placebo (n = 20) in a double-blind design using matched-pair randomization according to ileal resection length in patients without detectable inflammatory activity. Under controlled hospital conditions, absolute output volumes were measured and response was defined as a reduction in intestinal output of > 25% compared to pretreatment conditions.
RESULTS: In the treatment group, we observed an absolute decrease in median intestinal output from 1,240 ml to 865 ml (30.2%), compared to 0.3% under placebo (from 950 ml to 947.5 ml). Response was documented in 60% (12/20 patients) in the treatment group compared to no response under placebo (P < 0.0001). While both treatment groups showed similar absolute median reductions (400 ml with ileal resection < or = 20 cm and 405 ml with ileal resection > 20 cm), the relative reduction (response rate) was lower in the subgroup of an ileal resection > 20 cm (36%) due to the greater increase in output secondary to the loss of ileum.
CONCLUSIONS: These data support the assumption that the absorptive capacity of the intestinal mucosa for water may be improved by topically acting steroids and suggest that this occurs independently of their anti-inflammatory effect.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12737444     DOI: 10.1080/00365520310000645a

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  5 in total

Review 1.  Ileostomy diarrhea: Pathophysiology and management.

Authors:  Kyle M Rowe; Lawrence R Schiller
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-01-30

2.  Ileostomy diarrhea.

Authors:  Andrew W DuPont; Joseph H Sellin
Journal:  Curr Treat Options Gastroenterol       Date:  2006-02

3.  Budesonide as induction therapy for incomplete microscopic colitis: A randomised, placebo-controlled multicentre trial.

Authors:  Andreas Münch; Emese Mihaly; Ferenc Nagy; Ahmed Madisch; Juozas Kupčinskas; Stephan Miehlke; Johan Bohr; Gerd Bouma; Jordi Guardiola; Blanca Belloc; Chunliang Shi; Daniela Aust; Ralf Mohrbacher; Roland Greinwald; Lars Kristian Munck
Journal:  United European Gastroenterol J       Date:  2021-08-20       Impact factor: 6.866

Review 4.  Budesonide for maintenance of remission in Crohn's disease.

Authors:  M Ellen Kuenzig; Ali Rezaie; Cynthia H Seow; Anthony R Otley; A Hillary Steinhart; Anne Marie Griffiths; Gilaad G Kaplan; Eric I Benchimol
Journal:  Cochrane Database Syst Rev       Date:  2014-08-21

Review 5.  Chronic intestinal failure and short bowel syndrome in Crohn's disease.

Authors:  Aysegül Aksan; Karima Farrag; Irina Blumenstein; Oliver Schröder; Axel U Dignass; Jürgen Stein
Journal:  World J Gastroenterol       Date:  2021-06-28       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.